Pachybasin

Pachybasin

SCHEMBL7624909

Cc1cc(O)c2c(c1)C(=O)c1ccccc1C2=O

nearest known ligand 0.75

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.75
ELANE P08246 4/20 0.75
ALDH1A1 P00352 4/20 0.75
MEN1 O00255 4/20 0.75
KMT2A Q03164 4/20 0.75
CYP3A4 P08684 3/20 0.75
MAPK1 P28482 3/20 0.75
TDP1 Q9NUW8 3/20 0.75
KDM4E B2RXH2 3/20 0.75
TSHR P16473 2/20 0.75
BRCA1 P38398 2/20 0.75
RECQL P46063 2/20 0.75
USP2 O75604 1/20 0.75
BCL2 P10415 3/20 0.68
MCL1 Q07820 3/20 0.68
ALOX15 P16050 3/20 0.66
MAOA P21397 3/20 0.66
CYP1A1 P04798 2/20 0.66
MAOB P27338 2/20 0.66
CYP1B1 Q16678 2/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pachybasin SCHEMBL31536859 1.00 MAPT (0.75) MAPTELANEALDH1A1MEN1KMT2A
SCHEMBL11077084 0.93 MAPT (0.65) MAPTELANEALDH1A1MEN1KMT2A
Chrysophanol SCHEMBL9879838 0.90 ALDH1A1 (0.94) MAPTELANEALDH1A1MEN1KMT2A
SCHEMBL19461856 0.87 ALDH1A1 (0.90) MAPTELANEALDH1A1MEN1KMT2A
SCHEMBL12304029 0.86 ELANE (0.85) MAPTELANEALDH1A1MEN1KMT2A
Chrysophanol SCHEMBL8674524 0.86 ALDH1A1 (1.00) MAPTELANEALDH1A1MEN1KMT2A
Chrysophanol SCHEMBL29364442 0.86 ALDH1A1 (1.00) MAPTELANEALDH1A1MEN1KMT2A
Chrysophanol SCHEMBL308131 0.86 ALDH1A1 (1.00) MAPTELANEALDH1A1MEN1KMT2A
Chrysophanol SCHEMBL30457995 0.86 ALDH1A1 (1.00) MAPTELANEALDH1A1MEN1KMT2A
Chrysophanol SCHEMBL29730935 0.86 ALDH1A1 (1.00) MAPTELANEALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117683195-A Anthraquinone modified polyurethane and preparation method and application thereof 厦门理工学院 2024-03-12 CN claimed
EP-3943085-A2 TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION ETH Zurich (CH) 2022-01-26 EP claimed
US-20210186947-A1 TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION ETH ZURICH (CH) 2021-06-24 US claimed
EP-3801507-A2 TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION ETH Zurich (CH) 2021-04-14 EP claimed
US-20180146683-A1 NEW PRODUCT ALPHA BIOPESTICIDES LIMITED (GB) 2018-05-31 US claimed
CN-107846904-A New product 阿尔法生物农药有限公司 2018-03-27 CN claimed
CN-105778404-A Flame retardant insulation foam material and preparation method thereof 苏州甫众塑胶有限公司 2016-07-20 CN claimed
CN-117683195-A Anthraquinone modified polyurethane and preparation method and application thereof 厦门理工学院 2024-03-12 CN disclosed
WO-2023199238-A1 NOVEL COMPOUNDS TO TREAT CYTOKINE RELATED DISORDERS ZYDUS LIFESCIENCES LIMITED (IN) 2023-10-19 WO disclosed
WO-2023199238-A1 NOVEL COMPOUNDS TO TREAT CYTOKINE RELATED DISORDERS ZYDUS LIFESCIENCES LIMITED (IN) 2023-10-19 WO disclosed
CN-107846904-B New product 阿尔法生物农药有限公司 2022-02-08 CN disclosed
EP-3943085-A2 TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION ETH Zurich (CH) 2022-01-26 EP disclosed
US-20210186947-A1 TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION ETH ZURICH (CH) 2021-06-24 US disclosed
WO-2016189329-A1 NEW PRODUCT ALPHA BIOPESTICIDES LIMITED (GB) 2016-12-01 WO disclosed
CN-105778404-A Flame retardant insulation foam material and preparation method thereof 苏州甫众塑胶有限公司 2016-07-20 CN disclosed
CN-1106375-C Method for preparing substd. anthraguinone and application to preparation of rheins GIREX (FR) 2003-04-23 CN disclosed
EP-0909268-B1 METHOD FOR PREPARING SUBSTITUTED ANTHRAQUINONE AND APPLICATION TO THE PREPARATION OF RHEINS GIREX (FR) 2002-06-05 EP disclosed
EP-0801639-B1 METHOD FOR PREPARING SUBSTITUTED ANTHRAQUINONES AND USE THEREOF FOR PREPARING RHEINS GIREX (FR) 2002-01-02 EP disclosed
US-6057461-A Method for preparing substituted anthraquinone and application to the preparation of rheins GIREX (FR) 2000-05-02 US disclosed
CN-1216035-A METHOD FOR PREPARING SUBSTD. ANTHRAGUINONE AND APPLICATION TO PREPARATION OF RHEINS GIREX (FR) 1999-05-05 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180146683-A1 NEW PRODUCT CYP51A1, ERG28, FASN MAPT 3981/4885ELANE 4160/4885ALDH1A1 1756/4885
US-20210186947-A1 TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION TOMM70, TOMM34, TIMM50 MAPT 2071/4885ELANE 4808/4885ALDH1A1 3685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.